{"success":true,"data":{"pressRelease":{"id":"139012","rtpr_id":"nBw7wlqCxa-20260909","ticker":"KAPA","exchange":"NYSE American","all_tickers":["KAPA"],"title":"Kairos Pharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference","author":"Business Wire","published_at":"2026-09-09T12:00:00.212Z","article_body":"Kairos Pharma to Present at the H.C. Wainwright 28(th) Annual Global\nInvestment Conference\n\nKairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical\ncompany focused on overcoming cancer drug resistance, announces that John Yu,\nMD, CEO and Chairman, will present in person a corporate overview at the H.C.\nWainwright 28(th) Annual Global Investment Conference. The conference is being\nheld on September 14 – 16, 2026 at the Lotte New York Palace Hotel.\n\nPresentation Date: September 14, 2026\n\nTime: 4:00 PM Eastern Time (Holmes 1)\n\nWebcast Link: Available Here\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fjourney.ct.events%2Fview%2Feda75be8-1a00-4c5f-a6cf-3f463d938f29&esheet=54599079&newsitemid=20260909429715&lan=en-US&anchor=Available+Here&index=1&md5=122dfbc1acfbc249a468e6d0996128bf)\n\nA webcast of the presentation can be accessed on the investor relations\nsection of the Kairos Pharma website. A replay of the webcast will be archived\nand available following the event for 90 days.\n\nDr. Yu will be available for one-on-one meetings throughout the conference. To\nrequest a meeting and to register for the conference, click below:\n\nhttps://hcwevents.com/annualconference/\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fhcwevents.com%2Fannualconference%2F&esheet=54599079&newsitemid=20260909429715&lan=en-US&anchor=https%3A%2F%2Fhcwevents.com%2Fannualconference%2F&index=2&md5=096d63dd83cc2057b08f6cdf24cb9130)\n\nAbout Kairos Pharma Ltd.\n\nBased in Los Angeles, California, Kairos Pharma Ltd. (NYSE American: KAPA) is\nat the forefront of oncology therapeutics, utilizing structural biology to\novercome drug resistance and immune suppression in cancer. Kairos Pharma’s\nlead candidate, ENV-105, is an antibody that targets CD105—a protein\nidentified as a key driver of resistance and disease relapse in response to\nstandard therapy. ENV-105 aims to reverse drug resistance by targeting CD105\nand restore the effectiveness of standard therapies across multiple cancer\ntypes. For more information, visit kairospharma.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fkairospharma.com&esheet=54599079&newsitemid=20260909429715&lan=en-US&anchor=kairospharma.com&index=3&md5=681190c0188b285aa2e902bb9646af23)\n.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260909429715/en/\n(https://www.businesswire.com/news/home/20260909429715/en/)\n\nCORE IR\n\ninvestors@kairospharma.com \n(mailto:investors@kairospharma.com) \nhttps://investors.kairospharma.com/overview/default.aspx\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Finvestors.kairospharma.com%2Foverview%2Fdefault.aspx&esheet=54599079&newsitemid=20260909429715&lan=en-US&anchor=https%3A%2F%2Finvestors.kairospharma.com%2Foverview%2Fdefault.aspx&index=4&md5=ea7dba97e34567a8575c78c2423b11ae)\n\n\nCopyright Business Wire 2026","article_body_html":"","raw_payload":{"data":{"id":"nBw7wlqCxa-20260909","title":"Kairos Pharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference","author":"Business Wire","ticker":"KAPA","created":"2026-09-09T12:00:00.212Z","tickers":["KAPA"],"exchange":"NYSE American","article_body":"Kairos Pharma to Present at the H.C. Wainwright 28(th) Annual Global\nInvestment Conference\n\nKairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical\ncompany focused on overcoming cancer drug resistance, announces that John Yu,\nMD, CEO and Chairman, will present in person a corporate overview at the H.C.\nWainwright 28(th) Annual Global Investment Conference. The conference is being\nheld on September 14 – 16, 2026 at the Lotte New York Palace Hotel.\n\nPresentation Date: September 14, 2026\n\nTime: 4:00 PM Eastern Time (Holmes 1)\n\nWebcast Link: Available Here\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fjourney.ct.events%2Fview%2Feda75be8-1a00-4c5f-a6cf-3f463d938f29&esheet=54599079&newsitemid=20260909429715&lan=en-US&anchor=Available+Here&index=1&md5=122dfbc1acfbc249a468e6d0996128bf)\n\nA webcast of the presentation can be accessed on the investor relations\nsection of the Kairos Pharma website. A replay of the webcast will be archived\nand available following the event for 90 days.\n\nDr. Yu will be available for one-on-one meetings throughout the conference. To\nrequest a meeting and to register for the conference, click below:\n\nhttps://hcwevents.com/annualconference/\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fhcwevents.com%2Fannualconference%2F&esheet=54599079&newsitemid=20260909429715&lan=en-US&anchor=https%3A%2F%2Fhcwevents.com%2Fannualconference%2F&index=2&md5=096d63dd83cc2057b08f6cdf24cb9130)\n\nAbout Kairos Pharma Ltd.\n\nBased in Los Angeles, California, Kairos Pharma Ltd. (NYSE American: KAPA) is\nat the forefront of oncology therapeutics, utilizing structural biology to\novercome drug resistance and immune suppression in cancer. Kairos Pharma’s\nlead candidate, ENV-105, is an antibody that targets CD105—a protein\nidentified as a key driver of resistance and disease relapse in response to\nstandard therapy. ENV-105 aims to reverse drug resistance by targeting CD105\nand restore the effectiveness of standard therapies across multiple cancer\ntypes. For more information, visit kairospharma.com\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fkairospharma.com&esheet=54599079&newsitemid=20260909429715&lan=en-US&anchor=kairospharma.com&index=3&md5=681190c0188b285aa2e902bb9646af23)\n.\n\n\n\nView source version on businesswire.com:\nhttps://www.businesswire.com/news/home/20260909429715/en/\n(https://www.businesswire.com/news/home/20260909429715/en/)\n\nCORE IR\n\ninvestors@kairospharma.com \n(mailto:investors@kairospharma.com) \nhttps://investors.kairospharma.com/overview/default.aspx\n(https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Finvestors.kairospharma.com%2Foverview%2Fdefault.aspx&esheet=54599079&newsitemid=20260909429715&lan=en-US&anchor=https%3A%2F%2Finvestors.kairospharma.com%2Foverview%2Fdefault.aspx&index=4&md5=ea7dba97e34567a8575c78c2423b11ae)\n\n\nCopyright Business Wire 2026"},"type":"article","timestamp":"2026-09-09T12:00:00.245068534Z","server_sent_at_ms":1788955200245},"received_at":"2026-09-09T12:00:00.327Z","source_url":"https://www.businesswire.com/news/home/20260909429715/en/"},"analysis":{"id":"127854","press_release_id":"139012","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Kairos Pharma (NYSE American: KAPA) announced that CEO and Chairman John Yu, MD, will present a corporate overview in person at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026 at 4:00 PM ET.\n\nThe conference runs September 14-16, 2026 at the Lotte New York Palace Hotel; a webcast will be available on the company's investor relations site with a replay archived for 90 days, and Dr. Yu will be available for one-on-one meetings throughout the event.\n\nKairos is a Los Angeles-based clinical-stage oncology company whose lead candidate ENV-105, an antibody targeting CD105, aims to reverse drug resistance and restore the effectiveness of standard cancer therapies.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine conference appearance -- low signal on its own, but watch the September 14 webcast for any pipeline updates on ENV-105."},"keyFigures":{},"namedEntities":{"people":[{"name":"John Yu, MD","role":"CEO and Chairman"}],"products":["ENV-105"],"companies":[{"name":"Kairos Pharma, Ltd.","ticker":"KAPA","relationship":"filer"},{"name":"H.C. Wainwright","relationship":"conference host / investment bank"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine investor-conference scheduling announcement with no new clinical, financial, or strategic information disclosed. Boilerplate corporate-communications release."},"tickerRelevance":{"others":[],"primary":"KAPA"},"globalImportance":5,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"conference-presentation-boilerplate","issuerAuthored":true,"clinicalStagePreRevenue":true}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Kairos Pharma (NYSE American: KAPA) announced that CEO and Chairman John Yu, MD, will present a corporate overview in person at the H.C. Wainwright 28th Annual Global Investment Conference on September 14, 2026 at 4:00 PM ET.\n\nThe conference runs September 14-16, 2026 at the Lotte New York Palace Hotel; a webcast will be available on the company's investor relations site with a replay archived for 90 days, and Dr. Yu will be available for one-on-one meetings throughout the event.\n\nKairos is a Los Angeles-based clinical-stage oncology company whose lead candidate ENV-105, an antibody targeting CD105, aims to reverse drug resistance and restore the effectiveness of standard cancer therapies.","key_figures":{},"named_entities":{"people":[{"name":"John Yu, MD","role":"CEO and Chairman"}],"products":["ENV-105"],"companies":[{"name":"Kairos Pharma, Ltd.","ticker":"KAPA","relationship":"filer"},{"name":"H.C. Wainwright","relationship":"conference host / investment bank"}],"dollarAmounts":[]},"model_name":"glm-5.3-flash","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-09T12:00:19.816Z","global_importance":5,"audience_relevance":10,"importance_components":{"tickerTier":"micro-cap","eventGravity":"conference-presentation-boilerplate","issuerAuthored":true,"clinicalStagePreRevenue":true}},"durationMs":19479,"modelName":"glm-5.3-flash"}}